Array Biopharma Incorporated (NASDAQ: ARRY) was downgraded by Zacks Investment Research from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday.
Separately, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Array Biopharma Incorporated in a research note to investors on Monday, December 12nd. They now have a $6.00 price target on the stock.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Array Biopharma Incorporated opened at 2.75 on Wednesday. Array Biopharma Incorporated has a 52-week low of $1.58 and a 52-week high of $3.41. The stock has a 50-day moving average of $2.2 and a 200-day moving average of $2.24. The company’s market cap is $160.6 million.
Stay on top of analysts' coverage with our daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day. Click here to register.